Skip to main content

Table 4 Recent reports on stereotactic body radiation therapy for lung or liver metastases

From: Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence

Aurhor (reference)

Lesion /Patients, n

CRC rate, %

Median f/u period, m

Median MTD, mm

Median GTV, mL

LC, %

PFS, %

OS, %

AE ≥ G3, %

1 yr

2 yr

1 yr

2 yr

1 yr

2 yr

Rusthoven (7)

63/ 38

24

15

NA

4.2

100

96

NA

NA

NA

39

8

Rurthoven (8)

63/ 47

32

16

27

14.9

95

92

NA

NA

NA

30

2

Binkley (10)

122/ 77

21

22

NA

3.7

91

84

NA

25

94

75

0

Andratschke (13)

91/ 52

42

17

28

NA

NA

82

35

18

70

45

1.9(≥G2)

Ricard (14)

77/ 61

21

20

NA

NA

NA

89

NA

32

NA

67

2

Filippi (15)

59/ 40

100

46

15

NA

93

NA

49

27

84

73

7.5(≥G2)

Agolli (16)

69/ 44

100

36

14

NA

NA

NA

NA

20

NA

68

0

Katz (17)

74/ 69

29

15

27

NA

76

57

24

NA

78

37

0

Scorsetti (18)

52/ 42

100

24

35

NA

95

91

NA

46

NA

65

0

Joo (19)

103/ 70

100

34

29

NA

93

89

NA

35

NA

75

NA

Wang (25)

134/ 95

18

17

NA

14.6

98

91

51

29

83

61

3

Vautrauers-Dewas (26)

62/ 42

67

14

25

13

90

86

NA

NA

94

48

6.3

Present study

114/ 76

61

21

19

3.2

89

78

38

20

96

76

1.3

  1. CRC colorectal cancer, MTD maximum tumor diameter, GTV gross tumor volume, LC local control, PFS progression free survival, OS overall survival, AE adverse event, NA: